中华眼底病杂志

中华眼底病杂志

玻璃体腔注射康柏西普辅助全身药物系统治疗非感染性难治性葡萄膜炎黄斑水肿九例

查看全文

关键词: 葡萄膜炎/并发症; 黄斑水肿/药物疗法; 血管生成抑制剂/治疗应用; 抗体单克隆/治疗应用

引用本文: 谢洪彬, 杨美娜, 梁思颖, 王欣, 周敏, 陈青山. 玻璃体腔注射康柏西普辅助全身药物系统治疗非感染性难治性葡萄膜炎黄斑水肿九例. 中华眼底病杂志, 2017, 33(6): 639-641. doi: 10.3760/cma.j.issn.1005-1015.2017.06.022 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Tallouzi MO, Moore DJ, Calvert M, et al. The effectiveness of pharmacological agents for the treatment of uveitic macular oedema (UMO): a systematic review protocol[J]. Systematic Reviews, 2016, 5: 29. DOI: 10.1186/s13643-016-0203-y.
2. 姜允彬, 王泓. 难治性葡萄膜炎黄斑水肿的治疗进展[J]. 中华眼底病杂志, 2017, 33(1): 96-99. DOI:10.3760/cma.j.issn.1005-1015.2017.01.031.Jiang YB, Wang H. Advances in treatment of refractory uveitic macular edema[J]. Chin J Ocul Fundus Dis, 2017, 33(1): 96-99. DOI:10.3760/cma.j.issn.1005-1015.2017.01.031.
3. Wang Q, Li T, Wu Z, et al. Novel VEGF decoy receptor fusion protein conbercept targeting multiple VEGF isoforms provide remarkable anti-angiogenesis effect in vivo[J/OL]. PLoS One, 2013, 8(8): 70544[2013-08-12]. http://dx.plos.org/10.1371/journal.pone.0070544. DOI: 10.1371/journal.pone.0070544.
4. Lu X, Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration[J]. Drug Des Devel Ther, 2015, 9: 2311-2320. DOI: 10.2147/DDDT.S67536.
5. Al-Dhibi H, Hamade IH, Al-Halafi A, et al. The effects of intravitreal bevacizumab in infectious and noninfectious uveitic macular edema[J/OL]. J Ophthalmol, 2014, 2014: 729465[2014-07-21]. https://dx.doi.org/10.1155/2014/729465. DOI: 10.1155/2014/729465.
6. Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study[J]. Ophthalmology, 2014, 121(9): 1740-1747. DOI: 10.1016/j.ophtha.2014.03.026.
7. Zhang M, Zhang J, Yan M, et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration[J]. Ophthalmology, 2011, 118(4): 672-678. DOI: 10.1016/j.ophtha.2010.08.008.
8. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the first international workshop[J]. Am J Ophthalmol, 2005, 140(3): 509-516.
9. Singer MA, Awh CC, Sadda S, et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration[J]. Ophthalmology, 2012, 119(6): 1175-1183. DOI: 10.1016/j.ophtha.2011.12.016.
10. Acharya NR, Hong KC, Lee SM. Ranibizumab for refractory uveitis-related macular edema[J].Am J Ophthalmol, 2009, 148(2): 303-309. DOI: 10.1016/j.ajo.2009.03.028.